NASDAQ:ARAV

Aravive Stock Forecast, Price & News

$4.14

-0.20 (-4.61 %)

(As of 07/29/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.12

▼

$4.40

50-Day Range

$4.11

▼

$5.98

52-Week Range

$3.97

▼

$9.95

Volume76,319 shs

Average Volume383,333 shs

Market Capitalization$85.76 million

P/E RatioN/A

Dividend YieldN/A

Beta3.1

30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

About Aravive

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Aravive, Inc. (NASDAQ:ARAV) Sees Large Decrease in Short Interest
July 29, 2021 | americanbankingnews.com

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference - GlobeNewswire
July 28, 2021 | globenewswire.com

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference - Yahoo Finance
July 27, 2021 | finance.yahoo.com

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
July 27, 2021 | finance.yahoo.com

Aravive, Inc. (NASDAQ:ARAV) Receives Consensus Rating of "Buy" from Brokerages
July 24, 2021 | americanbankingnews.com

$1.94 Million in Sales Expected for Aravive, Inc. (NASDAQ:ARAV) This Quarter
July 24, 2021 | americanbankingnews.com

3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170% - Yahoo Finance
July 22, 2021 | finance.yahoo.com

Zacks: Analysts Expect Aravive, Inc. (NASDAQ:ARAV) to Post -$0.41 EPS
July 22, 2021 | americanbankingnews.com

Aravive Achieves Second Development Milestone from 3D Medicines - GlobeNewswire
July 17, 2021 | globenewswire.com

Form 8-K Aravive, Inc. For: Jul 15 - StreetInsider.com
July 15, 2021 | streetinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARAV
Previous Symbol
CUSIPN/A
CIK1513818
Webwww.aravive.com
Phone936-355-1910
Employees17
Year FoundedN/A

Sales & Book Value

Annual Sales$5.68 million
Price / Sales15.10
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.99 per share
Price / Book1.38

Profitability

EPS (Most Recent Fiscal Year)($1.64)
Net Income$-30,540,000.00
Net MarginsN/A
Return on Equity-49.21%
Return on Assets-38.65%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares20,714,000
Market Cap$85.76 million
Next Earnings Date8/2/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.34 out of 5 stars

Medical Sector

69th out of 2,214 stocks

Pharmaceutical Preparations Industry

30th out of 869 stocks

3.4 Analyst's Opinion

Consensus Rating
Aravive has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.20, Aravive has a forecasted upside of 508.7% from its current price of $4.14.
Amount of Analyst Coverage
Aravive has received no research coverage in the past 90 days.

3.3 Community Rank

Outperform Votes
Aravive has received 93 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aravive has received 46 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aravive has received 66.91% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote “Outperform” if you believe ARAV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aravive does not currently pay a dividend.
Dividend Growth
Aravive does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aravive insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,340.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
30.50% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
31.87% of the stock of Aravive is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Aravive are expected to decrease in the coming year, from ($1.80) to ($1.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aravive is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aravive is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aravive has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Aravive (NASDAQ:ARAV) Frequently Asked Questions

Is Aravive a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive or view top-rated stocks.

What stocks does MarketBeat like better than Aravive?

Wall Street analysts have given Aravive a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aravive wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aravive?

Aravive saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 777,900 shares, a decrease of 48.8% from the June 30th total of 1,520,000 shares. Based on an average daily trading volume, of 592,800 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.7% of the shares of the company are sold short.
View Aravive's Short Interest.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.44) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.01. The business earned $0.26 million during the quarter, compared to analysts' expectations of $0.57 million.
View Aravive's earnings history.

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have decreased by 17.0% and is now trading at $4.14.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ARAV?

6 Wall Street analysts have issued 12-month price objectives for Aravive's shares. Their forecasts range from $20.00 to $30.00. On average, they expect Aravive's stock price to reach $25.20 in the next year. This suggests a possible upside of 508.7% from the stock's current price.
View analysts' price targets for Aravive or view top-rated stocks among Wall Street analysts.

Who are Aravive's key executives?

Aravive's management team includes the following people:

Dr. Gail F. McIntyre, Pres, CEO & Director (Age 58, Pay $562.47k)
Mr. Vinay Shah, Chief Financial Officer (Age 59, Pay $481.99k)
Dr. Raymond Tabibiazar M.D., Advisor
Dr. Reshma Rangwala M.D., Ph.D., Chief Medical Officer (Age 43, Pay $144.07k)
Dr. Jeffrey L. Cleland, Co-Founder (Age 56)
Dr. Joshua Silverman Ph.D., Co-Founder
Joseph T. Schepers, VP of Investor Relations
Dr. Randy L. Anderson, Sr. VP of Data Sciences
Kenneth L. Guernsey, Sec.

Who are some of Aravive's key competitors?

Some companies that are related to Aravive include Verona Pharma (VRNA), Theratechnologies (THTX), Cue Biopharma (CUE), GX Acquisition (GXGX), UroGen Pharma (URGN), Angion Biomedica (ANGN), Oncorus (ONCR), Celularity (CELU), MEI Pharma (MEIP), Impel NeuroPharma (IMPL), Puma Biotechnology (PBYI), Aeglea BioTherapeutics (AGLE), 89bio (ETNB), Fortress Biotech (FBIO) and Verrica Pharmaceuticals (VRCA).
View all of ARAV's competitors.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $4.14.

How much money does Aravive make?

Aravive has a market capitalization of $85.76 million and generates $5.68 million in revenue each year. The company earns $-30,540,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Aravive have?

Aravive employs 17 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

Where are Aravive's headquarters?

Aravive is headquartered at River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here